Metabolite Identification Data in Drug Discovery, Part 1: Data Generation and Trend Analysis
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Marie Ahlqvist und 7 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZenec…. Hauptthemen laut MEDLINE: Drug Discovery. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In drug discovery, metabolite identification data are used to identify metabolic soft spots in research molecules to facilitate reduced metabolism in subsequently designed compounds. In addition, knowledge about exact metabolite structures enables the assessment of risks associated with active, reactive, or toxic metabolites. In the present work, we exemplify how metabolite identification data are generated and utilized at AstraZeneca. We share metabolite transformation scheme data derived from incubations in human hepatocytes for a set of 120 compounds. Comparison with other in-house generated metabolite identification data, both in terms of chemical space analysis and in vitro properties, is performed, including the characterization of observed metabolic pathways. For selected compounds, the correlation between in vitro and in vivo metabolite data in animal species is provided. Finally, the usage of shared metabolite identification data for drug metabolism prediction using machine learning and artificial intelligence approaches is discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 83 Mölndal, Sweden.
- Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 83 Mölndal, Sweden.
- Department of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
ORCID-Profile: Marie Ahlqvist, Filip Miljković, Ya Chen, Susanne Winiwarter
Zitieren
APA
Ahlqvist, M., Bonner Karlsson, I., Ekdahl, A., Ericsson, C., Jurva, U., Miljković, F., Chen, Y., & Winiwarter, S. (2025). Metabolite Identification Data in Drug Discovery, Part 1: Data Generation and Trend Analysis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00738
Vancouver
Ahlqvist M, Bonner Karlsson I, Ekdahl A, Ericsson C, Jurva U, Miljković F, et al. Metabolite Identification Data in Drug Discovery, Part 1: Data Generation and Trend Analysis. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00738
BibTeX
@article{Ahlqvist2025,
author = {Ahlqvist, Marie and Bonner Karlsson, Isabella and Ekdahl, Anja and Ericsson, Cecilia and Jurva, Ulrik and Miljković, Filip and Chen, Ya and Winiwarter, Susanne},
title = {Metabolite Identification Data in Drug Discovery, Part 1: Data Generation and Trend Analysis},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00738}
}
EUVIMED